Drug resistance in acute myeloid leukemias;Les tests de resistance aux medicaments en oncologie: L'exemple des leucemies aigues myeloides (LAM)

Hematologie

Volumn 2, Issue 5, 1996, Pages 417-425

  Lacombe, Francis ^a   Belloc, Francis ^a   Viallard, Jean François ^a   Grosset, Christophe ^a   Bernard, Philippe ^a   Reiffers, Josy ^a  

^a HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

acute leukemia; chemosensitivity

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYTARABINE; DAUNORUBICIN; VERAPAMIL;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; HUMAN; MULTIDRUG RESISTANCE; REVIEW;

EID: 0029857810     PISSN: 12647527     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Bosanquet AG. Correlations between therapeutic response of leukemias and in vitro drug-sensitivity assay. Lancet 1991; 337: 711-4.
2. Twenlyman PR, Fox NE, Rees JKH. Chemo-sensitivity testing of fresh leukaemia cells using the MTT colorimetric assay. Br J Haematol 1989; 71: 19-24.
3. Pieters R, Huismans DR, Loonen AH, Hählen K, van der Does-van den Berg A, van Wering ER, Veerman AJP. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukemia. Lancet 1991; 338: 399-403.
4. Larsson R, Kristensen J, Sandberg C, Nygren P. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer 1992; 50: 177-85.
5. Nara N, Curtis JE, Senn JS, Tritchler DL, McCulloch EA. The sensitivity to cytosine arabinoside of the blast progenitors in acute myeloblastic leukemia. Blood 1986; 67: 762-9.
6. Delmer A, Marie JP, Thevenin D, Cadiou M, Viguíé F, Zittoun R. Multivariate analysis of pronostic factors in acute myeloid leukemia: value of clonogenic leukemic cell properties. J Clin Oncol 1989; 7: 738-46.
7. Griffin JD, Löwenberg B. Clonogenic cells in acute myeloblastic leukemia. Blood 1986; 68: 1185-95.
8. Inatomi Y, Toyama K, Clark SC, Shimizu K, Miyauchi J. Combinations of stem cell factor with other hematopoietic factors enhance growth and sensitivity to cytosine arabinoside of blast progenitors in acute myelogenous leukemia. Cancer Res 1994; 54: 455-62.
9. Koistinen P, Wang C, Curtis JE, McCulloch E. Granulocyte-macrophage colony-stimulating factor and interleukin-3 protect leukemic blast cells from Ara-C toxicity. Leukemia 1991; 5: 789-95.
10. Preisler HD, Raza A. Cell cycle studies in acute myelogenous leukemia. Leukemia 1992; 6: 751-4.
11. Lacombe F, Belloc F. Cell proliferation markers in acute leukemia. Leuk Lymph 1994; 13 (suppl. 1): 23-6.
12. 3HTdr. Leuk Res 1987; 11: 1079-85.
13. Riccardi A, Danova M, Wilson G, Ucci G, Dormer P, Mazzini G, Brugnatelli S, Girino M, McNally NJ, Ascari E. Cell kinetics in human malignancies studied with in vivo administration of bromodeoxyuridine and flow cytometry. Cancer Res 1988; 48: 6238-45.
14. Vidriales MB, Orfao A, Lopes-Berges MC, Gonzalez M, Lopez-Macedo A, Ciudad J, Lopez A, Garcia MA, Hernandez J, Borrego D, San Miguel JF. Prognostic value of S-phase cells in AML patients. Br J Haematol 1995; 89: 342-8.
15. Lacombe F, Belloc F, Dumain P, Puntous M, Cony-Makoul P, Saux MC, Bernard P, Boisseau MR, Reiffers J. Detection of cytarabine resistance in patients with acute myelogenous leukemia using flow cytometry. Blood 1994; 84: 716-23.
16. Momparler R, Onetto-Pothier N. Drug resistance to cytosine arabinoside. In : Kessel D, ed. Resistance to antineoplastic drugs. Boca Raton: CRC Press, 1989: 353-67.
17. Stegmann APA, Honders WH, Willemze R, Ruiz van Haperen VWT, Landegeni JE. Transfection of wild-type deoxycytidine kinase (dck) cDNA onto an Ara-C and DAC-resistant rat leukemic cell line of clonal origin fully restores drug sensitivity. Blood 1995; 85: 1188-94.
18. Lacombe F, Bellac F, Dumain P, Puntous M, Lopez F, Bernard P, Boisseau MR, Reiffers J. Quantitation of resistance of leukemic cells to cytosine arabinoside from BrdUrd/DNA bivariate histograms. Cytometry 1992; 13: 730-8.
19. Zhou DC, Marie JP, Suberville AM, Zittoun R. Relevance of mdr1 gene expression in acute myeloid leukemia and comparison of different diagnostic methods. Leukemia 1992; 6: 879-85.
20. Marie JP, Faussat-Suberville AM, Dacheng Z, Zittoun R. Daunorubicin uptake by leukemic cells: correlations with treatment outcome and mdr1 expression. Leukemia 1993; 7: 825-31.
21. Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, Fiere D. Clinical significance of muitidrug resistance P-glycoprotein expression on acute non-lymphoblastic leukemia cells at diagnosis. Blood 1992; 79: 473-6.
22. + acute myeloid leukemia cells. Blood 1993; 82: 3157-63.
23. Lamy T, Goasguen JE, Mordelet E, Grulois I, Dauriac C, Drenou B, Chaperon J, Fauchet R, le Prise PY. P-glycoprotein (P-170) and CD34 expression in adult acute myeloid leukemia (AML). Leukemia 1994; 8: 1879-83.
24. Maslak P, Hegewish-Becker S, Godfrey L, Andreeff M. Flow cytometric determination of the multidrug-resisiant phenotype in acute leukemia. Cytometry 1994; 17: 84-93.
25. Holmes JA, West RR. The effect of mdr-1 gene expression on outcome in acute myeloblastic leukemia. Br J Cancer 1994; 69: 382-4.
26. Brophy NA, Marie JP, Rojas VA, Warnke RA, McFall PJ, Smith SD, Sikic BI. mdr1 gene expression in childhood acute lymphoblastic leukemias and lymphomas: a critical evaluation by four techniques. Leukemia 1994; 8: 327-35.
27. Beck J, Handgrefinger R, Dopfer R, Klingebiel T, Niethammer D, Gekeler V. Expression of mdr1, mrp, topoisomerase II α/β, and cyclin A in primary or relapsed states of acute lymphoblastic leukemias. Br J Haematol 1995; 89: 356-63.
28. McKenna SL, West RR, Whittaker JA, Padua RA, Holmes JA. Topoisomerase II α expression in acute myeloid leukemia and its relationship to clinical outcome. Leukemia 1994; 8: 1498-502.
29. Burger H, Nooter K, Zaman GJR, Sonneveld P, van Wingerden KE, Oostrum RG, Stoter G. Expression of the multidrug resistance associated protein (MRP) in acute and chronic leukemia. Leukemia 1994; 8: 990-7.
30. Kuss BJ, Deeley RG, Cole SPC, Willman CL, Kopecky KJ, Wolman SR, Eyre HJ, Lane SA, Nancarrow JK, Whitmore SA, Callen DF. Deletion of gene for multidrug resistance in acute myeloid leukemia with inversion in chromosome 16: prognostic implications. Lancet 1994; 343: 1531-4.
31. Tiirikainen MI, Elonen E, Syrjälä MT, Jansson ST, Krusius T. Flow cytometric analysis of glutathione-S-transferaseπ in acute leukemia. Leukemia 1994; 8: 978-84.
32. Gunji H, Kharbanda S, Kufe D. Induction of internucleosomal DNA fragmentation in human myeloid leukemia cells by 1-β-D-arabinofuranosylcytosine. Cancer Res 1991; 51: 741-3.
33. Gorczyca W, Bigman K, Mittelman A, Ahmed T, Gong J, Melamed MR, Darzynkiewicz Z. Induction of DNA strand breaks associated with apoptosis during treatment of leukemias. Leukemia 1993; 7: 659-70.
34. Belloc F, Dumain P, Boisseau MR, Jalloustre C, Reiffers J, Bernard Ph, Lacombe F. A flow cytometric method using Hoechst 33342 and propidium iodide for simultaneous cell cycle analysis and apoptosis determination in unfixed cells. Cytometry 1994; 17: 59-65.
35. Vial JP, Belloc F, Schmit V, Dumain P, Lacombe F, Boisseau MR, Bernard P, Reiffers J. Étude par cytométrie en flux de l'apoptose induite in vitro par les anthracyclines, l'Ara-C et la mitoxantrone sur la lignée cellulaire U397. Bull Cancer 1994; 81: 972-5.
36. Browman G, Preisler H. Predicting remission outcome in acute non-lymphoblastic leukemia: general principles and their application to residual marrow leukemia. Leuk Res 1992; 16: 511-9.